Literature DB >> 23652560

Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population.

Xiaofei Zhang1, Pengli Yu, Ying Wang, Wenyu Jiang, Fangcheng Shen, Yamin Wang, Huiming Tu, Xiaozhong Yang, Ruihua Shi, Hongjie Zhang.   

Abstract

OBJECTIVE: Interleukin-17A and interleukin-17F (IL-17A and IL-17F) are candidate genes for chronic inflammatory disease. We investigated the association between IL17A/F gene polymorphisms and susceptibility to and clinical features of inflammatory bowel disease (IBD).
METHODS: A total of 270 ulcerative colitis (UC) patients, 82 Crohn's disease (CD) patients and 268 healthy controls were recruited in this study. Genomic DNA was extracted and analyzed for IL17A/F gene polymorphisms using ligase detection reaction allelic technology.
RESULTS: Compared to the controls, the mutant allele C for IL17F rs763780 was significantly more common in CD patients [14.0 vs 8.4 %, P = 0.033, odds ratio (OR) 1.18, 95 % confidence interval (CI) 1.41-3.04] and was associated with the disease lesion location. This variant of IL17F rs763780 also had a weak correlation with the age of UC onset (P = 0.05, OR 0.97, 95 % CI 0.94-1.00). The IL17A (rs2275913, G-197A) variant had a weak association with the severity of disease: patients with the mutant allele A tended to suffer mild active UC. The haplotype (GGTT) of IL17A formed with four single nucleotide polymorphisms (rs2275913, rs8193037, rs8193038, and rs3804513) was associated with an increased risk of UC (P = 0.034, OR 4.58, 95 % CI 1.54-13.64).
CONCLUSIONS: The IL17F (rs763780, 7488T/C) variant was associated with an increased risk for the development of CD, and affected some clinical features of UC and CD. The IL17A (rs2275913, G-197A) variant had a weak association with the severity of UC. There was a risk haplotype in IL17A which could increase the risk of UC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652560     DOI: 10.1007/s00011-013-0629-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  37 in total

Review 1.  The IL-17 family cytokines in immunity and disease.

Authors:  Rajita Pappu; Vladimir Ramirez-Carrozzi; Naruhisa Ota; Wenjun Ouyang; Yan Hu
Journal:  J Clin Immunol       Date:  2010-02-23       Impact factor: 8.317

2.  Ulcerative colitis: factors affecting difficulties of life and psychological well being of patients in remission.

Authors:  Makoto Tanaka; Keiko Kazuma
Journal:  J Clin Nurs       Date:  2005-01       Impact factor: 3.036

3.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

4.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

5.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

6.  An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment.

Authors:  Spencer C Liang; Andrew J Long; Frann Bennett; Matthew J Whitters; Riyez Karim; Mary Collins; Samuel J Goldman; Kyriaki Dunussi-Joannopoulos; Cara M M Williams; Jill F Wright; Lynette A Fouser
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

7.  Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population.

Authors:  Bin Chen; Zhirong Zeng; Jiangtao Hou; Minhu Chen; Xiang Gao; Pinjin Hu
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

Review 8.  The genetic basis of inflammatory bowel disease.

Authors:  Rachel Cooney; Derek Jewell
Journal:  Dig Dis       Date:  2009-11-04       Impact factor: 2.404

Review 9.  Interleukin-23/Th17 pathways and inflammatory bowel disease.

Authors:  Clara Abraham; Judy Cho
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

10.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

View more
  15 in total

1.  Effects of endoplasmic reticulum stress on the expression of inflammatory cytokines in patients with ulcerative colitis.

Authors:  Nan Li; Xue-Ming Wang; Li-Jun Jiang; Meng Zhang; Na Li; Zhen-Zhen Wei; Nan Zheng; Ya-Jiao Zhao
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: a meta-analysis.

Authors:  Juan Li; Hao Tian; Hui-Jun Jiang; Bin Han
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population.

Authors:  S Y Kim; M S Hur; B G Choi; M J Kim; Y W Lee; Y B Choe; K J Ahn
Journal:  Clin Exp Immunol       Date:  2016-11-24       Impact factor: 4.330

4.  Association of single nucleotide polymorphisms of IL23R and IL17 with necrotizing enterocolitis in premature infants.

Authors:  Jiayi Tian; Yanjun Liu; Yanfang Jiang; Haohan Zhou; Tong Zhu; Xiaoqi Zhao; Liping Peng; Chaoying Yan
Journal:  Mol Cell Biochem       Date:  2017-02-21       Impact factor: 3.396

5.  Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymorphisms with non-segmental vitiligo in a Mexican population.

Authors:  Natalia Aranza Zapata-Salazar; David Emmanuel Kubelis-Lopez; Mauricio Andres Salinas-Santander; Celia Nohemi Sanchez-Dominguez; Ana Cecilia Xolalpa-Rosales; Marely Eugenia Gomez-Galindo; Jorge Ocampo-Candiani
Journal:  Arch Dermatol Res       Date:  2022-08-12       Impact factor: 3.033

6.  Significant association between interleukin-17A polymorphism and colorectal cancer.

Authors:  Inés Omrane; Raja Marrakchi; Olfa Baroudi; Amel Mezlini; Hager Ayari; Imen Medimegh; Nejla Stambouli; Nadia Kourda; Hassen Bouzaienne; Nancy Uhrhammer; Karim Bougatef; Yves-Jean Jean Bignon; Amel Benammar-Elgaaied
Journal:  Tumour Biol       Date:  2014-04-04

7.  Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy.

Authors:  Inés Omrane; Imen Medimegh; Olfa Baroudi; Hager Ayari; Walid Bedhiafi; Nejla Stambouli; Marwa Ferchichi; Nadia Kourda; Yves-Jean Bignon; Nancy Uhrhammer; Amel Mezlini; Karim Bougatef; Amel Benammar-Elgaaied
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  Interleukin-17A gene haplotypes are associated with risk of premature coronary artery disease in Mexican patients from the Genetics of Atherosclerotic Disease (GEA) study.

Authors:  Gilberto Vargas-Alarcón; Javier Angeles-Martínez; Teresa Villarreal-Molina; Edith Alvarez-León; Rosalinda Posadas-Sánchez; Guillermo Cardoso-Saldaña; Julian Ramírez-Bello; Nonanzit Pérez-Hernández; Juan Gabriel Juárez-Rojas; José Manuel Rodríguez-Pérez; José Manuel Fragoso; Carlos Posadas-Romero
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

Review 9.  The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.

Authors:  Daniele Noviello; Riccardo Mager; Giulia Roda; Riccardo G Borroni; Gionata Fiorino; Stefania Vetrano
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

10.  Association between IL17A and IL17F polymorphisms and risk of Henoch-Schonlein purpura in Chinese children.

Authors:  Hui Xu; Yanxiang Pan; Wei Li; Haidong Fu; Junfeng Zhang; Hongqiang Shen; Xiucui Han
Journal:  Rheumatol Int       Date:  2016-03-28       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.